Publications by authors named "Keith L Ligon"

100Publications

WNT-Activated Medulloblastomas With Hybrid Molecular Subtypes.

JCO Precis Oncol 2020 14;4. Epub 2020 Apr 14.

Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/PO.19.00332DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7446405PMC
April 2020

Loss of H3K27me3 and nuclear expression of TLE1 in primary intracranial sarcoma, DICER1-mutant.

Histopathology 2020 Jul 21. Epub 2020 Jul 21.

Department of Pathology, Boston Children's Hospital, Harvard Medical School, Boston, United States.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/his.14217DOI Listing
July 2020

Epigenomic programming in early fetal brain development.

Epigenomics 2020 Jun 17;12(12):1053-1070. Epub 2020 Jul 17.

Department of Microbiology & Immunology, Michael Smith Laboratories, University of British Columbia, Vancouver, BC, V6T 1Z4, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/epi-2019-0319DOI Listing
June 2020

Prediction of Outcomes with a Computational Biology Model in Newly Diagnosed Glioblastoma Patients Treated with Radiation Therapy and Temozolomide.

Int J Radiat Oncol Biol Phys 2020 Nov 14;108(3):716-724. Epub 2020 May 14.

Department of Radiation Oncology, Dana-Farber/Brigham and Women's Cancer Center, Harvard Medical School, Boston, MA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ijrobp.2020.05.010DOI Listing
November 2020

Mechanisms and therapeutic implications of hypermutation in gliomas.

Nature 2020 04 15;580(7804):517-523. Epub 2020 Apr 15.

Department of Oncologic Pathology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41586-020-2209-9DOI Listing
April 2020

Longitudinal molecular trajectories of diffuse glioma in adults.

Nature 2019 12 20;576(7785):112-120. Epub 2019 Nov 20.

The Jackson Laboratory for Genomic Medicine, Farmington, CT, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41586-019-1775-1DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6897368PMC
December 2019

Tie2-FGFR1 Interaction Induces Adaptive PI3K Inhibitor Resistance by Upregulating Aurora A/PLK1/CDK1 Signaling in Glioblastoma.

Cancer Res 2019 10 15;79(19):5088-5101. Epub 2019 Aug 15.

Brain Tumor Center, Departments of Neuro-Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/0008-5472.CAN-19-0325DOI Listing
October 2019

An Integrative Model of Cellular States, Plasticity, and Genetics for Glioblastoma.

Cell 2019 08 18;178(4):835-849.e21. Epub 2019 Jul 18.

Department of Pathology and Center for Cancer Research, Massachusetts General Hospital and Harvard Medical School, Boston, MA, 02114, USA; Klarman Cell Observatory, Broad Institute of Harvard and MIT, Cambridge, MA 02142, USA; Broad Institute of Harvard and MIT, Cambridge, MA 02142, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.cell.2019.06.024DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6703186PMC
August 2019

CHD4 regulates the DNA damage response and RAD51 expression in glioblastoma.

Sci Rep 2019 03 14;9(1):4444. Epub 2019 Mar 14.

Division of Oncology, Department of Medicine, Washington University School of Medicine, St. Louis, MO, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41598-019-40327-wDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6418088PMC
March 2019

Recurrent EP300-BCOR Fusions in Pediatric Gliomas With Distinct Clinicopathologic Features.

J Neuropathol Exp Neurol 2019 04;78(4):305-314

Department of Pathology, Boston Children's Hospital and Harvard Medical School, Boston, Massachusetts.

View Article

Download full-text PDF

Source
https://academic.oup.com/jnen/advance-article/doi/10.1093/jn
Publisher Site
http://dx.doi.org/10.1093/jnen/nlz011DOI Listing
April 2019

Microfluidic active loading of single cells enables analysis of complex clinical specimens.

Nat Commun 2018 11 14;9(1):4784. Epub 2018 Nov 14.

Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, USA.

View Article

Download full-text PDF

Source
http://www.nature.com/articles/s41467-018-07283-x
Publisher Site
http://dx.doi.org/10.1038/s41467-018-07283-xDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6235965PMC
November 2018

Vemurafenib and cobimetinib overcome resistance to vemurafenib in -mutant ganglioglioma.

Neurology 2018 09 17;91(11):523-525. Epub 2018 Aug 17.

From Sorbonne Université (M.T., A.I., M.S., A.L.D.S.), Inserm, CNRS, UMR S 1127, Institut du Cerveau et de la Moelle épinière, ICM, AP-HP, Hôpitaux Universitaires La Pitié Salpêtrière-Charles Foix, Service de Neurologie 2-Mazarin, Paris, France; Department of Oncologic Pathology (M.T., K.L.L.), Dana-Farber/Brigham and Women's Cancer Center, Harvard Medical School, Boston, MA; Department of Neuroradiology (J.G., S.C.A.), Pharmacy Department (K.S.), and Departments of Neurosurgery (S.A.), Pathology (C.V.), and Neurology (A.L.D.S.), Hôpital Foch, Suresnes; Department of Radiology (J.S.), Fondation Ophtalmologique Adolphe de Rothschild, Paris; Département de Génétique (G.P., A.-P.G.-R., P.L.-P.), and Service de Biochimie, UF de Pharmacogénétique et Oncologie Moléculaire (H.B.), Assistance Publique Hôpitaux de Paris, Hôpital Européen Georges-Pompidou, Paris; INSERM (G.P., H.B., P.L.-P.), UMR S 1147, Paris; Drug Development Department (A.H.), Gustave Roussy, Université Paris-Saclay, Villejuif; INSERM (A.-P.G.-R.), UMR970, Paris-Cardiovascular Research Center, Equipe Labellisée par la Ligue contre le Cancer, Paris; and Université Paris Descartes (H.B., A.-P.G.-R., P.L.-P.), Sorbonne Paris Cité, Faculté de Médecine, Paris, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1212/WNL.0000000000006171DOI Listing
September 2018

The FDA NIH Biomarkers, EndpointS, and other Tools (BEST) resource in neuro-oncology.

Neuro Oncol 2018 08;20(9):1162-1172

Department of Radiation Oncology, Dana-Farber/Brigham and Women's Cancer Center, Harvard Medical School, Boston, Massachusetts.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/neuonc/nox242DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6071649PMC
August 2018

A novel GIT2-BRAF fusion in pilocytic astrocytoma.

Diagn Pathol 2017 Nov 15;12(1):82. Epub 2017 Nov 15.

Department of Pathology, Boston Children's Hospital, 300 Longwood Ave, Bader, Boston, MA, 02115, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s13000-017-0669-5DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5688665PMC
November 2017

Brainstem angiocentric gliomas with MYB-QKI rearrangements.

Acta Neuropathol 2017 Oct 12;134(4):667-669. Epub 2017 Aug 12.

Department of Pathology, Sainte-Justine Hospital, Université de Montréal, Montréal, QC, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00401-017-1763-1DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6556888PMC
October 2017

Therapeutic and Prognostic Implications of BRAF V600E in Pediatric Low-Grade Gliomas.

J Clin Oncol 2017 Sep 20;35(25):2934-2941. Epub 2017 Jul 20.

Alvaro Lassaletta, Michal Zapotocky, Matthew Mistry, Vijay Ramaswamy, Marion Honnorat, Rahul Krishnatry, Ana Guerreiro Stucklin, Nataliya Zhukova, Anthony Arnoldo, Scott Ryall, Catriona Ling, Tara McKeown, Jim Loukides, James T. Rutka, Peter Dirks, Michael D. Taylor, Shiyi Chen, Ute Bartels, Annie Huang, Eric Bouffet, Cynthia Hawkins, and Uri Tabori, The Hospital for Sick Children, Toronto; Adam Fleming, McMaster Children's Hospital, McMaster University, Hamilton; Shayna Zelcer, Children's Hospital of Western Ontario, London, Ontario; David Eisenstat and Bev Wilson, Stollery Children's Hospital, University of Alberta, Edmonton, Alberta; Anne Sophie Carret, Hospital Sainte Justine; Nada Jabado, McGill University, Montreal; Valerie Larouche, Centre Hospitalier Universitaire de Québec, Québec City, Quebec, Canada; Ofelia Cruz and Carmen de Torres, Hospital Sant Joan de Déu, Barcelona, Spain; Cheng-Ying Ho, University of Maryland School of Medicine, Baltimore, MD; Roger J. Packer, Children's National Health System, Washington, DC; Ruth Tatevossian, Ibrahim Qaddoumi, Julie H. Harreld, James D. Dalton, and David W. Ellison, St Jude Children's Research Hospital, Memphis, TN; Jean Mulcahy-Levy and Nicholas Foreman, Children's Hospital Colorado, Aurora, CO; Matthias A. Karajannis, Shiyang Wang, and Matija Snuderl, New York University Langone Medical Center, New York, NY; Amulya Nageswara Rao and Caterina Giannini, The Mayo Clinic, Rochester, MN; Mark Kieran and Keith L. Ligon, Dana-Farber Cancer Institute, Boston Children's Hospital, Boston, MA; Maria Luisa Garre, Paolo Nozza, Samantha Mascelli, and Alessandro Raso, Istituto Giannina Gaslini, Genoa, Italy; Sabine Mueller and Theodore Nicolaides, University of California, San Francisco, San Francisco, CA; Karen Silva and Romain Perbet, Hospices Civils de Lyon; Alexandre Vasiljevic, Cécile Faure Conter, and Didier Frappaz, Institute of Pediatric Hematology and Oncology, Lyon, France; Sarah Leary and Courtney Crane, Seattle Children's Hospital, Seattle, WA; Aden Chan and Ho-Keung Ng, The Chinese University of Hong Kong, Hong Kong; Zhi-Feng Shi and Ying Mao, Huashan Hospital, Fudan University, Shanghai, People's Republic of China; Elizabeth Finch, University of North Carolina, School of Medicine, Chapel Hill, NC; Peter Hauser, Semmelweis University, Budapest, Hungary; and David Sumerauer and Lenka Krskova, University Hospital Motol, Charles University, 2nd Medical School, Prague, Czech Republic.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2016.71.8726DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5791837PMC
September 2017

Nuclear CRX and FOXJ1 Expression Differentiates Non-Germ Cell Pineal Region Tumors and Supports the Ependymal Differentiation of Papillary Tumor of the Pineal Region.

Am J Surg Pathol 2017 Oct;41(10):1410-1421

*Department of Pathology, Brigham and Women's Hospital, Harvard Medical School ‡Department of Pathology, Boston Children's Hospital, Harvard Medical School Departments of §Medical Oncology ¶Cancer Biology, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA †Department of Pathology and Immunology, Washington University School of Medicine, St. Louis, MO ∥East Pathology and Neuropathology Center, East Hospital Group, University Hospital of Lyon Bron, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/PAS.0000000000000903DOI Listing
October 2017

Clinical Identification of Oncogenic Drivers and Copy-Number Alterations in Pituitary Tumors.

Endocrinology 2017 07;158(7):2284-2291

Center for Skull Base and Pituitary Surgery, Department of Neurosurgery, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts 02115.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1210/en.2016-1967DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5505210PMC
July 2017

Leveraging molecular datasets for biomarker-based clinical trial design in glioblastoma.

Neuro Oncol 2017 Jul;19(7):908-917

Department of Radiation Oncology, Department of Pathology, Center for Neuro-Oncology, Dana-Farber/Brigham & Women's Cancer Center (DF/BWCC), Harvard Medical School, Boston, Massachusetts; Department of Biostatistics, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts; Accelerate Brain Cancer Cure (ABC2), Washington, DC; Harvard Program in Therapeutic Science, Harvard Medical School, Boston, Massachusetts.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/neuonc/now312DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5570228PMC
July 2017

Clinical targeted exome-based sequencing in combination with genome-wide copy number profiling: precision medicine analysis of 203 pediatric brain tumors.

Neuro Oncol 2017 Jul;19(7):986-996

Dana-Farber/Boston Children's Cancer and Blood Disorders Center, Department of Pathology, Department of Radiology, Department of Neurosurgery, Boston Children's Hospital, Boston, Massachusetts; Department of Medical Oncology, Oncologic Pathology, Department of Pediatric Oncology, Department of Cancer Biology, Center for Cancer Genome Discovery, Dana-Farber Cancer Institute, Boston, Massachusetts; Department of Pathology, Department of Neurosurgery, Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts; Pratiti Bandopadhayay, Broad Institute of MIT and Harvard, Boston, Massachusetts; Harvard Medical School, Boston, Massachusetts.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/neuonc/now294DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5570190PMC
July 2017

Genomic characterization of recurrent high-grade astroblastoma.

Cancer Genet 2016 Jul-Aug;209(7-8):321-30. Epub 2016 Jun 21.

Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA; Center for Molecular Oncologic Pathology, Dana Farber Cancer Institute, Boston, MA, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.cancergen.2016.06.002DOI Listing
May 2017

Tyrosine receptor kinase B is a drug target in astrocytomas.

Neuro Oncol 2017 01 10;19(1):22-30. Epub 2016 Jul 10.

Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, Massachusetts (J.N., S.X., V.L., Y.S., P.B., R.B., T.M.R., C.D.S., R.A.S., J.J.Z.); Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, Massachusetts (J.N., S.X., V.L., T.M.R., J.J.Z.); Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts (S.H.R., R.B., K.L.L., W.C.H.); Broad Institute, Boston, Massachusetts (P.B., R.B., W.C.H.); Department of Pathology, Brigham and Women's Hospital, Boston, Massachusetts (S.H.R., K.L.L.); Department of Pathology, Boston Children's Hospital, Boston, Massachusetts (K.L.L.)

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/neuonc/now139DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5193024PMC
January 2017

Post-translational Modifications of OLIG2 Regulate Glioma Invasion through the TGF-β Pathway.

Cell Rep 2016 07 7;16(4):950-966. Epub 2016 Jul 7.

Division of Neurobiology, Barrow Brain Tumor Research Center, Barrow Neurological Institute, St. Joseph's Hospital and Medical Center, Phoenix, AZ 85013, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.celrep.2016.06.045DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4963280PMC
July 2016

Multimodal MRI features predict isocitrate dehydrogenase genotype in high-grade gliomas.

Neuro Oncol 2017 01 26;19(1):109-117. Epub 2016 Jun 26.

Department of Radiology, Brigham and Women's Hospital, Boston, Massachusetts (B.Z., K.C., R.Y.H.); Department of Pathology, Brigham and Women's Hospital, Boston, Massachusetts (S.R., K.L.L.); Department of Pathology, Harvard Medical School, Boston, Massachusetts (S.R., K.L.L.); Department of Pathology, Boston Children's Hospital, Boston, Massachusetts (S.R., K.L.L.); Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts(S.R., D.A.R., K.L.L., P.Y.W.); Harvard Radiation Oncology Program, Boston, Massachusetts (S.T.); Department of Neurosurgery, Brigham and Women's Hospital, Boston, Massachusetts (W.L.B.); Center of Neuro-Oncology, Dana-Farber/Brigham and Women's Cancer Center, Boston, Massachusetts (D.A.R., P.Y.W.); Department of Radiation Oncology, Dana-Farber/Brigham and Women's Cancer Center, Boston, Massachusetts (B.M.A.)

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/neuonc/now121DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5193019PMC
January 2017

Oncogenic PI3K mutations are as common as AKT1 and SMO mutations in meningioma.

Neuro Oncol 2016 05 28;18(5):649-55. Epub 2016 Jan 28.

Department of Pathology, Brigham and Women's Hospital, Boston, Massachusetts (M.A., P.H.M., R.B., M.L.L., S.H.R., R.D.F., K.L.L., A.H.L., S.S.); Department of Pathology, King Fahad Medical City, Riyadh, Saudi Arabia (M.A.); King Abdulaziz City for Science and Technology, Riyadh, Saudi Arabia (M.A.); Harvard Medical School, Boston, Massachusetts (M.A., A.A.A., D.D.-S., P.K.B., D.A.R., P.Y.W., O.A.-M., S.H.R., R.D.F., K.L.L., A.H.L., B.M.A., I.F.D., R.B., S.S.); Department of Neurosurgery, Brigham and Women's Hospital, Boston, Massachusetts (W.L.B., O.A.-M., I.F.D.); Department of Radiation Oncology, Brigham and Women's Hospital, Boston, Massachusetts (A.A.A., B.M.A.); Department of Neurosurgery, Massachusetts General Hospital, Boston, Massachusetts (P.K.A.); Department of Pathology, Massachusetts General Hospital, Boston, Massachusetts (D.D.-S.); Center for Cancer Genomic Discovery, Dana-Farber Cancer Institute, Boston, Massachusetts (A.R.T., P.V.H.); Department of Neuro-Oncology, Massachusetts General Hospital, Boston, Massachusetts (P.K.B.); Center of Neuro-Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts (D.A.R., P.Y.W, R.B.); Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts (K.L.L., R.B.); Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA (S.S.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/neuonc/nov316DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4827048PMC
May 2016

Case Report: Next generation sequencing identifies a NAB2-STAT6 fusion in Glioblastoma.

Diagn Pathol 2016 Jan 27;11:13. Epub 2016 Jan 27.

Department of Pathology, Brigham and Women's Hospital, 75 Francis Street, Boston, MA, 02115, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s13000-016-0455-9DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4729030PMC
January 2016

Decreased FOXJ1 expression and its ciliogenesis programme in aggressive ependymoma and choroid plexus tumours.

J Pathol 2016 Mar;238(4):584-97

Department of Pathology, Division of Neuropathology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/path.4682DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5364032PMC
March 2016

Preclinical Efficacy of the MDM2 Inhibitor RG7112 in MDM2-Amplified and TP53 Wild-type Glioblastomas.

Clin Cancer Res 2016 Mar 19;22(5):1185-96. Epub 2015 Oct 19.

Inserm, U 1127, Paris, France. CNRS, UMR 7225, Paris, France. Sorbonne Universités, UPMC Univ Paris 06, UMR S 1127, Paris, France. Institut du Cerveau et de la Moëlle épinière, ICM, 47, Bd de l'Hôpital, Paris, France. AP-HP, Hôpital universitaire Pitié-Salpêtrière, Service de Neurologie 2-Mazarin, 47, Bd de l'Hôpital, Paris, France. AP-HP, Hôpital de la Pitié-Salpêtrière, Service de Neuropathologie R Escourolle, 47, Bd de l'Hôpital, Paris, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-15-1015DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4842012PMC
March 2016

Orally administered colony stimulating factor 1 receptor inhibitor PLX3397 in recurrent glioblastoma: an Ivy Foundation Early Phase Clinical Trials Consortium phase II study.

Neuro Oncol 2016 Apr 8;18(4):557-64. Epub 2015 Oct 8.

University of California at San Francisco, San Francisco, California (N.B., A.P., J.P., A.M.M, M.P.); Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah (H.C.); The University of Texas MD Anderson Cancer Center, Houston, Texas (J.F.D.G.); Department of Neurology, Memorial Sloan Kettering Cancer Hospital, New York, New York (A.M.O.); Center for Neuro-Oncology, Dana-Farber/Brigham and Women's Cancer Center, Boston, Massachusetts (L.N., P.Y.W., S.H., K.L.L.); UCLA Medical Center, Los Angeles, California (T.F.C.); Plexxikon Inc., Berkeley, California (A.M., B.L.W., K.B.N., H.H.H.); Department of Pathology, Brigham and Women's Hospital, Boston, Massachusetts (K.L.L.); Department of Pathology, Memorial Sloan Kettering Cancer Hospital, New York, New York (J.H.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/neuonc/nov245DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4799682PMC
April 2016

Somatic mutations associated with MRI-derived volumetric features in glioblastoma.

Neuroradiology 2015 Dec 4;57(12):1227-37. Epub 2015 Sep 4.

Department of Radiation Oncology, Dana-Farber Cancer Institute, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00234-015-1576-7DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4648958PMC
December 2015

A prognostic cytogenetic scoring system to guide the adjuvant management of patients with atypical meningioma.

Neuro Oncol 2016 Feb 30;18(2):269-74. Epub 2015 Aug 30.

Department of Radiation Oncology, Dana-Farber/Brigham and Women's Cancer Center, Boston, Massachusetts (A.A.A., M.C.H., N.D.A., B.M.A.); Department of Pathology, Dana-Farber/Brigham and Women's Cancer Center, Boston, Massachusetts (M.A., K.L.L., A.H.L., S.S.); Department of Neurosurgery, Dana-Farber/Brigham and Women's Cancer Center, Boston, Massachusetts (W.L.B., O.A-M., I.F.D.); Center for Neuro-Oncology, Dana-Farber/Brigham and Women's Cancer Center, Boston, Massachusetts (E.Q.L., L.N., M.L.R., A.D.N., D.A.R., P.Y.W., R.B.).

View Article

Download full-text PDF

Source
https://academic.oup.com/neuro-oncology/article-lookup/doi/1
Publisher Site
http://dx.doi.org/10.1093/neuonc/nov177DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4724184PMC
February 2016

Integrated Genomic Characterization of a Pineal Parenchymal Tumor of Intermediate Differentiation.

World Neurosurg 2016 Jan 28;85:96-105. Epub 2015 Jul 28.

Department of Neurosurgery, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.wneu.2015.07.032DOI Listing
January 2016

One size should not fit all: advancing toward personalized glioblastoma therapy.

Discov Med 2015 Jun;19(107):471-7

Center of Neuro-Oncology, Dana-Farber/Brigham and Women's Cancer Center, Harvard Medical School, Boston, MA 02215, USA.

View Article

Download full-text PDF

Source
June 2015

Toward precision medicine in glioblastoma: the promise and the challenges.

Neuro Oncol 2015 Aug 1;17(8):1051-63. Epub 2015 May 1.

University of California San Francisco, San Francisco, California (M.D.P, J.J.P., A.M.M., S.M.C.); Translational Genomics Research Institute, Phoenix, Arizona (S.A.B., N.L.T., W.D.T., J.A.K., M.E.B., D.W.C., J.D.C., J.M.T.); Dana-Farber/Brigham and Women's Cancer Center, Boston, Massachusetts (K.L.L., P.Y.W.); University of Texas Health Science Center, San Antonio, Texas (J.G.K.); Memorial Sloan-Kettering Cancer Center, New York, New York (I.K.M.); The University of Texas M.D. Anderson Cancer Center, Houston, Texas (J.F.d.G.); University of Utah Huntsman Cancer Institute, Salt Lake City, Utah (H.C.); University of California Los Angeles, Los Angeles, California (T.F.C.); Iowa Spine and Brain Institute, Waterloo, Iowa (T.C.R.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/neuonc/nov031DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4490873PMC
August 2015

Calibrating genomic and allelic coverage bias in single-cell sequencing.

Nat Commun 2015 Apr 16;6:6822. Epub 2015 Apr 16.

Cancer Program, Broad Institute of Harvard and MIT, Cambridge, Massachusetts 02142, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/ncomms7822DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4922254PMC
April 2015

SHMT2 drives glioma cell survival in ischaemia but imposes a dependence on glycine clearance.

Nature 2015 Apr 8;520(7547):363-7. Epub 2015 Apr 8.

1] Whitehead Institute for Biomedical Research, Nine Cambridge Center, Cambridge, Massachusetts 02142, USA [2] Howard Hughes Medical Institute and Department of Biology, Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, USA [3] The David H. Koch Institute for Integrative Cancer Research at MIT, 77 Massachusetts Avenue, Cambridge, Massachusetts 02139, USA [4] Department of Biology, Massachusetts Institute of Technology (MIT), Cambridge, Massachusetts 02139, USA [5] Broad Institute of Harvard and MIT, Seven Cambridge Center, Cambridge, Massachusetts 02142, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/nature14363DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4533874PMC
April 2015

Hypofractionated versus standard radiation therapy with or without temozolomide for older glioblastoma patients.

Int J Radiat Oncol Biol Phys 2015 Jun 1;92(2):384-9. Epub 2015 Apr 1.

Department of Radiation Oncology, Dana-Farber/Brigham and Women's Cancer Center, Harvard Medical School, Boston, Massachusetts. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ijrobp.2015.01.017DOI Listing
June 2015

Expression profiles of 151 pediatric low-grade gliomas reveal molecular differences associated with location and histological subtype.

Neuro Oncol 2015 Nov 29;17(11):1486-96. Epub 2015 Mar 29.

Department of Cancer Biology, Dana-Farber Cancer Institute, and Harvard Medical School, Boston, Massachusetts (G.B., P.B., B.R.P., S.E.S., B.T., R.F.-L., C.S., R.S., R.B.); Broad Institute, Cambridge, Massachusetts (G.B., P.B., B.R.P., S.E.S., B.T., R.F.-L., T.G., R.B.); Pediatric Neuro-Oncology Program, Dana-Farber/Boston Children's Cancer and Blood Disorders Center, Dana-Farber Cancer Institute and Boston Children's Hospital, and Harvard Medical School, Boston, Massachusetts (P.B., L.C.G., M.W.K.); Liver Cancer Program, Tisch Cancer Institute, Division of Liver Diseases, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, New York (Y.H.); Department of Pathology, Brigham and Women's Hospital, Boston, Massachusetts (S.R., S.S., P.Y.W., A.H.L., K.L.L., J.A.C.); Center for Molecular Oncologic Pathology, Dana-Farber Cancer Institute, Boston, Massachusetts (S.R., L.R., B.R., C.L.M., K.L.L.); Department of Neurosurgery, Acibadem University Medical Center, Istanbul, Turkey (M.O.); Department of Pathology, Acibadem University Medical Center, Istanbul, Turkey (A.S.); Department of Neurosurgery, Boston Children's Hospital, Boston, Massachusetts (L.C.G.); Departement de Cancerologie de l'enfant et de l'adolescent, Gustave Roussy and Unité Mixte de Recherche 8203 du Centre National de la Recherche Scientifique, Université Paris-Sud, Villejuif, France (J.G.); Department of Pathology, Boston Children's Hospital, Boston, Massachusetts (K.L.L.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/neuonc/nov045DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4648300PMC
November 2015

Clinical implementation of integrated whole-genome copy number and mutation profiling for glioblastoma.

Neuro Oncol 2015 Oct 9;17(10):1344-55. Epub 2015 Mar 9.

Center for Molecular Oncologic Pathology, Dana-Farber Cancer Institute, Boston, Massachusetts (S.H.R., L.A.R., S.H., D.K., Y.J.K., K.L.L.); Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts (S.E.S., L.B., M.B., D.A.R., E.Q.L., M.L.R., A.D.N., L.N., S.R., L.M.D., D.C.L., P.K., B.J.R., P.Y.W., R.B., K.L.L.); Department of Neurosurgery, Brigham and Women's Hospital, Boston, Massachusetts (W.L.B., E.B.C, O.A.-M., M.D.J., A.J.G., I.F.D., E.A.C.); Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston, Massachusetts (L.T.); Department of Radiation Oncology, Brigham and Women's Hospital, Boston, Massachusetts (M.H., A.A.A., N.D.A., B.M.A.); Department of Radiation Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts (M.H., A.A.A., N.D.A., B.M.A.); Harvard Radiation Oncology Program, Boston, Massachusetts (A.R.); Kravis Center for Molecular Oncology & Department of Epidemiology and Biostatistics, Memorial Sloan- Kettering Cancer Center, New York, New York (N.S.); Broad Institute, Cambridge, Massachusetts (R.B.); Department of Pathology, Boston Children's Hospital, Boston, Massachusetts (K.L.L.); Department of Pathology, Brigham and Women's Hospital, Boston, Massachusetts (S.H.R., A.D., J.B.C., M.A., S.S., R.D.F., N.I.L., A.H.L., K.L.L.)

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/neuonc/nov015DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4578577PMC
October 2015

BRAF mutation and CDKN2A deletion define a clinically distinct subgroup of childhood secondary high-grade glioma.

J Clin Oncol 2015 Mar 9;33(9):1015-22. Epub 2015 Feb 9.

Matthew Mistry, Nataliya Zhukova, Daniele Merico, Rahul Krishnatry, Mary Shago, James Stavropoulos, Noa Alon, Peter N. Ray, Vilma Navickiene, Joshua Mangerel, Marc Remke, Vijay Ramaswamy, Ana Guerreiro Stucklin, Martin Li, Edwin J. Young, Cindy Zhang, Pedro Castelo-Branco, Doua Bakry, Suzanne Laughlin, James T. Rutka, Peter B. Dirks, Michael D. Taylor, Mark Greenberg, David Malkin, Annie Huang, Eric Bouffet, Cynthia E. Hawkins, and Uri Tabori; The Hospital for Sick Children; Matthew Mistry, Patricia Rakopoulos, Rahul Krishnatry, Joshua Mangerel, Pawel Buczkowicz, Ana Guerreiro Stucklin, Doua Bakry, Adam Shlien, Mark Greenberg, David Malkin, Annie Huang, Eric Bouffet, Cynthia E. Hawkins, and Uri Tabori, University of Toronto; Jason D. Pole, Pediatric Oncology Group of Ontario, Toronto, Ontario; Jennifer Chan, Hotchkiss Brain Institute, University of Calgary, Calgary, Alberta, Canada; Pedro Castelo-Branco, Universidade do Algarve, Faro, Portugal; Keith L. Ligon, Dana-Farber/Boston Children's Cancer Center, Boston, MA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2014.58.3922DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4356711PMC
March 2015